INSYS Therapeutics, Inc.
INSYS Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2010, the company has made significant strides in developing innovative therapies, particularly in the areas of pain management and substance use disorders. INSYS is renowned for its unique delivery systems, including sublingual formulations that enhance the bioavailability of cannabinoids. Their flagship products, such as Syndros, have positioned the company as a leader in the treatment of chemotherapy-induced nausea and vomiting. With a commitment to advancing patient care, INSYS Therapeutics has achieved notable milestones, including successful FDA approvals and a growing portfolio of proprietary products. The company continues to focus on addressing unmet medical needs, solidifying its market position in the evolving landscape of therapeutics.
DitchCarbon Score
How does INSYS Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
INSYS Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
INSYS Therapeutics, Inc.'s reported carbon emissions
INSYS Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that INSYS may not have established formal commitments to address carbon emissions or climate change initiatives at this time. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and setting ambitious targets to reduce their carbon footprints. However, without specific emissions data or commitments from INSYS Therapeutics, it is challenging to assess their position relative to industry standards or peers.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
INSYS Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
